This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
mean age | 756 |
magnetic resonance | 744 |
image quality | 641 |
mr imaging | 592 |
imaging findings | 589 |
computed tomography | 534 |
pet ct | 525 |
learning objectives | 499 |
brain injury | 478 |
differential diagnosis | 474 |
one patient | 470 |
resonance imaging | 468 |
white matter | 463 |
lymph nodes | 450 |
fi ndings | 446 |
case report | 437 |
lymph node | 435 |
significant difference | 424 |
patients underwent | 412 |
aft er | 401 |
multiple sclerosis | 384 |
bone marrow | 383 |
blood flow | 366 |
risk factors | 355 |
statistically significant | 353 |
two groups | 353 |
signifi cant | 347 |
neurocritical care | 341 |
spinal cord | 338 |
care unit | 330 |
subarachnoid hemorrhage | 330 |
design method | 318 |
ct scan | 314 |
minimally invasive | 305 |
significantly higher | 304 |
soft tissue | 301 |
performed using | 296 |
ischemic stroke | 295 |
two patients | 295 |
breast cancer | 288 |
intensive care | 288 |
years old | 284 |
signal intensity | 279 |
significant differences | 278 |
consecutive patients | 278 |
united states | 271 |
mg kg | 267 |
nervous system | 266 |
pediatric patients | 262 |
contrast agent | 262 |
cardiac arrest | 257 |
traumatic brain | 254 |
magnetic field | 254 |
radiation dose | 252 |
control group | 251 |
status epilepticus | 247 |
patients received | 247 |
contrast agents | 246 |
patients admitted | 242 |
ct scans | 238 |
imaging modalities | 235 |
contrast enhancement | 230 |
spatial resolution | 229 |
median age | 228 |
hospital stay | 227 |
prostate cancer | 226 |
nuclear medicine | 226 |
logistic regression | 224 |
diagnostic accuracy | 223 |
patients treated | 221 |
whole body | 218 |
mr images | 215 |
weighted images | 213 |
coronary artery | 212 |
clinical practice | 211 |
imaging techniques | 209 |
small bowel | 208 |
patients undergoing | 208 |
year old | 206 |
medical center | 205 |
old male | 204 |
blood pressure | 203 |
within hours | 202 |
poor outcome | 198 |
retrospective study | 198 |
signifi cantly | 197 |
urinary tract | 196 |
weighted imaging | 194 |
three patients | 194 |
four patients | 193 |
chart review | 191 |
laparoscopic approach | 190 |
imaging features | 188 |
predictive value | 188 |
fdg pet | 183 |
procedure details | 181 |
retrospectively reviewed | 180 |
ct angiography | 180 |
central nervous | 177 |
imaging modality | 177 |
patients without | 177 |
gold standard | 176 |
methods materials | 176 |
intracerebral hemorrhage | 175 |
brain mri | 175 |
intracranial pressure | 174 |
prospective study | 174 |
cerebral edema | 172 |
clinical trials | 172 |
ct images | 171 |
femoral head | 171 |
significantly lower | 170 |
side effects | 170 |
statistical analysis | 168 |
adverse events | 167 |
rectal cancer | 165 |
high risk | 163 |
laparoscopic surgery | 162 |
increased risk | 160 |
five patients | 160 |
high resolution | 160 |
contrast medium | 157 |
operative time | 156 |
mg dl | 156 |
university hospital | 156 |
critical care | 155 |
ng ml | 154 |
slice thickness | 154 |
brain death | 154 |
mri findings | 154 |
functional outcome | 154 |
inclusion criteria | 152 |
renal function | 152 |
cerebral blood | 150 |
nerve conduction | 150 |
spiral ct | 149 |
old female | 149 |
radiation exposure | 149 |
retrospective review | 148 |
states background | 148 |
th ere | 147 |
critically ill | 147 |
myocardial perfusion | 146 |
present study | 146 |
blood loss | 145 |
retrospective chart | 145 |
intracranial hemorrhage | 145 |
lung cancer | 144 |
surgical treatment | 144 |
least one | 142 |
gastric cancer | 142 |
hospital mortality | 141 |
long term | 140 |
diffusion tensor | 139 |
important role | 138 |
fi rst | 138 |
one case | 137 |
regression analysis | 137 |
surgical intervention | 137 |
fl ow | 136 |
clinical data | 135 |
patients showed | 135 |
old woman | 135 |
case series | 134 |
sickle cell | 133 |
may also | 133 |
among patients | 133 |
adult patients | 133 |
peripheral neuropathy | 132 |
acute ischemic | 129 |
clinical presentation | 129 |
ml min | 129 |
corpus callosum | 129 |
contrast media | 129 |
medical records | 128 |
abdominal pain | 128 |
retrospective analysis | 128 |
contrast enhanced | 127 |
carotid artery | 127 |
imaging studies | 127 |
ct findings | 126 |
patients presenting | 125 |
ct imaging | 125 |
patients receiving | 125 |
peripheral nerve | 124 |
diagnostic imaging | 124 |
stem cell | 124 |
bile duct | 124 |
results suggest | 123 |
cohort study | 122 |
one year | 122 |
fdg uptake | 122 |
clinical features | 120 |
mr angiography | 120 |
chest ct | 119 |
age range | 119 |
significantly associated | 118 |
identifi ed | 118 |
body weight | 118 |
may help | 118 |
preliminary results | 118 |
two cases | 118 |
artery disease | 118 |
widely used | 117 |
heart rate | 117 |
weight loss | 117 |
year period | 117 |
pulmonary embolism | 117 |
old man | 116 |
perfusion imaging | 116 |
physical examination | 116 |
age years | 116 |
will also | 115 |
cerebrospinal fluid | 115 |
data sets | 115 |
emergency department | 115 |
brain tissue | 114 |
significantly different | 114 |
mechanical ventilation | 114 |
ill patients | 114 |
disease activity | 113 |
heart disease | 113 |
malignant lesions | 112 |
clinical course | 112 |
medical history | 111 |
head ct | 111 |
early diagnosis | 109 |
contrast material | 108 |
primary outcome | 108 |
low dose | 107 |
multivariate analysis | 107 |
clinical outcome | 107 |
stroke patients | 107 |
included patients | 106 |
determine whether | 106 |
aneurysmal subarachnoid | 106 |
cancer patients | 106 |
cerebral artery | 105 |
postoperative day | 104 |
radiation therapy | 104 |
renal failure | 104 |
six months | 104 |
standard deviation | 103 |
ct examinations | 102 |
patient population | 101 |
risk factor | 101 |
cerebral perfusion | 101 |
six patients | 101 |
cerebral ischemia | 100 |
helical ct | 100 |
colorectal cancer | 100 |
left ventricular | 100 |
clinical symptoms | 100 |
analysis showed | 99 |
postoperative complications | 99 |
myocardial infarction | 99 |
negative predictive | 99 |
overall survival | 99 |
eight patients | 99 |
severe tbi | 98 |
may occur | 98 |
good outcome | 98 |
commonly used | 97 |
healthy controls | 97 |
patients presented | 97 |
become familiar | 97 |
significant correlation | 97 |
clinical signs | 96 |
informed consent | 96 |
nine patients | 96 |
inflammatory demyelinating | 96 |
two years | 96 |
abdominal wall | 96 |
basal ganglia | 96 |
health care | 96 |
cell disease | 96 |
cell carcinoma | 95 |
term follow | 95 |
seven patients | 95 |
two different | 95 |
image fusion | 95 |
color doppler | 95 |
patient care | 95 |
enhanced ct | 95 |
clinical outcomes | 95 |
row ct | 95 |
dose reduction | 94 |
enhanced mri | 93 |
surgical resection | 93 |
final diagnosis | 93 |
temporal resolution | 93 |
data acquisition | 93 |
emission tomography | 92 |
glasgow coma | 92 |
therapeutic hypothermia | 92 |
diffusion coefficient | 92 |
modified rankin | 92 |
study period | 91 |
interventional radiology | 91 |
patient underwent | 91 |
metastatic disease | 91 |
clinical examination | 91 |
blood cell | 90 |
odds ratio | 90 |
spect ct | 90 |
pictorial review | 90 |
early detection | 90 |
within days | 90 |
pulmonary artery | 90 |
accurate diagnosis | 89 |
sah patients | 89 |
cell lines | 89 |
functional imaging | 89 |
imaging fi | 89 |
adc values | 89 |
high dose | 89 |
ct scanner | 88 |
clinical trial | 88 |
recent years | 88 |
mortality rate | 88 |
average age | 88 |
bone scintigraphy | 88 |
gamma camera | 87 |
tbi patients | 87 |
will discuss | 87 |
radical prostatectomy | 87 |
image noise | 87 |
medical imaging | 87 |
statistical significance | 87 |
wall thickening | 87 |
per patient | 86 |
month follow | 86 |
three months | 86 |
operation time | 86 |
one month | 86 |
tumor size | 86 |
noise ratio | 86 |
mri brain | 86 |
pilot study | 86 |
ten patients | 85 |
cervical spine | 85 |
study group | 85 |
last years | 85 |
data set | 85 |
body mass | 85 |
middle cerebral | 85 |
ich patients | 84 |
previous studies | 84 |
free survival | 84 |
two radiologists | 84 |
gray matter | 84 |
lung disease | 84 |
family history | 84 |
type i | 83 |
recent studies | 83 |
positron emission | 83 |
remaining patients | 83 |
may lead | 83 |
mri showed | 83 |
diagnostic value | 83 |
mmol kg | 83 |
clinical findings | 83 |
previously reported | 82 |
apparent diffusion | 82 |
patients developed | 82 |
presentation will | 82 |
disseminated encephalomyelitis | 82 |
diabetes mellitus | 82 |
diagnostic tool | 81 |
transverse magnetization | 81 |
acute stroke | 81 |
congenital heart | 81 |
healthy volunteers | 81 |
liver metastases | 81 |
neuropathic pain | 81 |
treatment options | 81 |
learning curve | 81 |
pediatric population | 81 |
mental status | 80 |
pleural effusion | 80 |
additional information | 80 |
blood volume | 80 |
neurological examination | 80 |
data suggest | 80 |
outcome measures | 80 |
patients diagnosed | 80 |
ct perfusion | 80 |
attenuation correction | 80 |
false positive | 80 |
imaging technique | 80 |
analyzed using | 79 |
cognitive impairment | 79 |
treatment response | 79 |
significant improvement | 79 |
temporal lobe | 79 |
enhanced mr | 79 |
mass index | 79 |
multislice ct | 79 |
evaluated using | 79 |
acute disseminated | 78 |
calculated using | 78 |
magnetic fields | 78 |
dynamic contrast | 78 |
node dissection | 78 |
may provide | 78 |
brain tumors | 78 |
coronary angiography | 77 |
lumbar spine | 77 |
schwann cells | 77 |
significantly increased | 77 |
pg ml | 77 |
coma scale | 77 |
endovascular treatment | 77 |
sentinel lymph | 77 |
first hours | 77 |
peripheral blood | 77 |
slice ct | 77 |
well tolerated | 76 |
benign lesions | 76 |
patient developed | 76 |
tensor imaging | 76 |
sectional imaging | 76 |
confi rmed | 76 |
gastric bypass | 75 |
image acquisition | 75 |
diagnostic criteria | 75 |
diff erence | 75 |
brain imaging | 75 |
cystic lesions | 75 |
ms patients | 74 |
clinical characteristics | 74 |
heart failure | 74 |
cidp patients | 74 |
chronic inflammatory | 74 |
vascular malformations | 74 |
colon cancer | 74 |
radiation protection | 74 |
selected patients | 74 |
portal vein | 74 |
defi ned | 74 |
will review | 74 |
respiratory failure | 74 |
abdominal ct | 74 |
lower limb | 74 |
intravenous immunoglobulin | 74 |
may result | 73 |
positive predictive | 73 |
patients may | 73 |
linear regression | 73 |
wide range | 73 |
false negative | 73 |
mean time | 72 |
three groups | 72 |
clinical information | 72 |
invasive surgery | 72 |
weighted mri | 72 |
statistically signifi | 72 |
high sensitivity | 72 |
laparoscopic cholecystectomy | 72 |
significantly reduced | 72 |
ejection fraction | 72 |
flow cytometry | 72 |
mr signal | 72 |
pediatric radiology | 72 |
sample size | 72 |
lower extremity | 72 |
diagnostic performance | 72 |
assessed using | 72 |
conduction studies | 71 |
lower limbs | 71 |
acute brain | 71 |
median time | 71 |
image reconstruction | 71 |
coronary arteries | 71 |
quantitative analysis | 71 |
risk patients | 71 |
static magnetic | 71 |
venous thrombosis | 71 |
study aimed | 71 |
hepatocellular carcinoma | 71 |
functional outcomes | 71 |
group i | 71 |
acquisition time | 71 |
radiofrequency ablation | 71 |
imaging methods | 71 |
patient presented | 70 |
young adults | 70 |
pediatric oncology | 70 |
diffi cult | 70 |
introduction purpose | 70 |
effective dose | 70 |
elderly patients | 70 |
observational study | 70 |
hernia repair | 69 |
pet imaging | 69 |
common cause | 69 |
one hundred | 69 |
mean follow | 69 |
bowel wall | 69 |
ct colonography | 69 |
disease progression | 69 |
correlation coefficient | 69 |
clinical diagnosis | 68 |
relaxation times | 68 |
diffusion weighted | 68 |
eff ects | 68 |
significant increase | 68 |
surgical procedure | 68 |
local recurrence | 68 |
obtained using | 68 |
head injury | 67 |
weighted mr | 67 |
may cause | 67 |
refractory status | 67 |
delayed cerebral | 67 |
useful tool | 67 |
wall thickness | 67 |
bowel obstruction | 67 |
quality improvement | 67 |
sleeve gastrectomy | 67 |
brain perfusion | 67 |
digital mammography | 67 |
mm slice | 67 |
mass effect | 66 |
study showed | 66 |
patient age | 66 |
positive correlation | 66 |
rankin scale | 66 |
mr system | 66 |
gbs patients | 66 |
measured using | 66 |
bone metastases | 66 |
poor prognosis | 66 |
vena cava | 66 |
discussion conclusion | 66 |
systematic review | 66 |
liver lesions | 66 |
field strength | 66 |
univariate analysis | 66 |
exclusion criteria | 66 |
decision making | 66 |
acute appendicitis | 66 |
left side | 66 |
tumour response | 65 |
total number | 65 |
optic nerve | 65 |
quality control | 65 |
month period | 65 |
regression model | 65 |
success rate | 65 |
literature review | 65 |
head trauma | 65 |
weighted sequences | 65 |
effi cacy | 65 |
disease severity | 65 |
symptom onset | 65 |
brain tumor | 65 |
natural history | 65 |
retrospective cohort | 65 |
factors associated | 65 |
cord uid | 65 |
doc id | 65 |
chest pain | 64 |
ich score | 64 |
thyroid cancer | 64 |
point scale | 64 |
identified patients | 64 |
longitudinal magnetization | 64 |
intracranial hypertension | 64 |
prognostic factors | 64 |
mri scans | 64 |
medical treatment | 64 |
iodinated contrast | 64 |
posterior fossa | 64 |
findings suggest | 64 |
patient management | 64 |
steady state | 64 |
confidence interval | 63 |
inversion recovery | 63 |
lymphoblastic leukemia | 63 |
relaxation time | 63 |
optic neuritis | 63 |
surgical technique | 63 |
molecular imaging | 63 |
mri images | 63 |
adverse effects | 63 |
even though | 63 |
tertiary care | 63 |
general anesthesia | 63 |
surgical approach | 62 |
discharged home | 62 |
acute lymphoblastic | 62 |
results indicate | 62 |
higher risk | 62 |
study aims | 62 |
external ventricular | 62 |
th day | 62 |
gene expression | 62 |
icu admission | 62 |
patient outcomes | 62 |
hospital discharge | 62 |
mri studies | 62 |
single center | 62 |
clinical evaluation | 62 |
ionizing radiation | 62 |
surgical procedures | 61 |
adjuvant chemotherapy | 61 |
significant reduction | 61 |
one week | 61 |
time points | 61 |
partial nephrectomy | 61 |
cerebral infarction | 61 |
case reports | 61 |
plasma exchange | 61 |
platelet count | 61 |
bladder cancer | 61 |
months later | 61 |
scoring system | 61 |
electronic medical | 61 |
gradient echo | 60 |
study included | 60 |
median nerve | 60 |
high grade | 60 |
median follow | 60 |
underwent laparoscopic | 60 |
early stage | 60 |
eff ective | 60 |
spin echo | 60 |
neurological deficits | 60 |
mm hg | 60 |
cant diff | 60 |
tube current | 60 |
jp purpose | 59 |
indocyanine green | 59 |
results show | 59 |
soft tissues | 59 |
midline shift | 59 |
group ii | 59 |
real time | 59 |
poor outcomes | 59 |
transverse myelitis | 59 |
open surgery | 59 |
analysis revealed | 59 |
digital subtraction | 58 |
internal carotid | 58 |
kg day | 58 |
age group | 58 |
different types | 58 |
independently associated | 58 |
differential diagnoses | 58 |
different imaging | 58 |
red blood | 58 |
renal cell | 58 |
per year | 58 |
controlled trial | 58 |
volume rendering | 57 |
subdural hematoma | 57 |
correct diagnosis | 57 |
intraventricular hemorrhage | 57 |
ct examination | 57 |
iterative reconstruction | 57 |
thyroid carcinoma | 57 |
prospectively collected | 57 |
three different | 57 |
image data | 57 |
female patients | 57 |
imaging characteristics | 57 |
ct showed | 57 |
skull base | 57 |
rheumatoid arthritis | 57 |
patients aged | 57 |
treated patients | 57 |
hypertonic saline | 57 |
fetal mri | 56 |
infl ammatory | 56 |
liver disease | 56 |
abdominal cavity | 56 |
ct data | 56 |
pathological findings | 56 |
complication rate | 56 |
dose ct | 56 |
medical record | 56 |
atrial fibrillation | 56 |
pd patients | 56 |
classifi ed | 56 |
examination revealed | 56 |
pulse sequences | 56 |
treatment planning | 56 |
neurological symptoms | 56 |
related complications | 56 |
family members | 56 |
days later | 56 |
echo sequences | 56 |
compared using | 56 |
treatment option | 55 |
less likely | 55 |
high frequency | 55 |
matter lesions | 55 |
independent predictor | 55 |
old girl | 55 |
blood vessels | 55 |
mr spectroscopy | 55 |
first step | 55 |
newly diagnosed | 55 |
year follow | 55 |
transcranial doppler | 55 |
patients died | 55 |
two weeks | 55 |
burst suppression | 55 |
hours post | 54 |
clinical suspicion | 54 |
gastrointestinal tract | 54 |
hearing loss | 54 |
baseline characteristics | 54 |
imaging using | 54 |
acute phase | 54 |
clinical use | 54 |
imaging biomarkers | 54 |
control subjects | 54 |
restricted diffusion | 54 |
hematoma expansion | 54 |
blood cultures | 54 |
detection rate | 54 |
mortality rates | 54 |
first line | 54 |
machine learning | 54 |
echo time | 54 |
receiver operating | 54 |
respiratory distress | 53 |
cranial nerve | 53 |
imaging plays | 53 |
nerve fibers | 53 |
recurrence rate | 53 |
months post | 53 |
renal masses | 53 |
many patients | 53 |
upper gi | 53 |
normal subjects | 53 |
tract infection | 53 |
large number | 53 |
selected cases | 53 |
subtraction angiography | 53 |
showed significant | 53 |
chest radiographs | 53 |
robotic surgery | 53 |
glasgow outcome | 53 |
aortic arch | 53 |
clinical applications | 52 |
functional mri | 52 |
previously described | 52 |
oncology patients | 52 |
commercially available | 52 |
renal artery | 52 |
bariatric surgery | 52 |
stem cells | 52 |
clinical improvement | 52 |
blood glucose | 52 |
wide spectrum | 52 |
gamma probe | 52 |
asah patients | 52 |
arterial phase | 52 |
high spatial | 52 |
enrolled patients | 51 |
normal range | 51 |
ich volume | 51 |
young children | 51 |
prospective studies | 51 |
cardiac ct | 51 |
rf pulse | 51 |
severe traumatic | 51 |
pelvic floor | 51 |
ct head | 51 |
right side | 51 |
higher incidence | 51 |
artery stenosis | 51 |
results showed | 51 |
classifi cation | 51 |
iron overload | 51 |
collected data | 51 |
pediatr radiol | 51 |
pulmonary nodules | 51 |
postoperative period | 51 |
cell transplantation | 51 |
high signal | 51 |
vein thrombosis | 51 |
leading cause | 51 |
chest wall | 51 |
tissue contrast | 50 |
multidetector ct | 50 |
case presentation | 50 |
supine position | 50 |
age groups | 50 |
patients required | 50 |
patient received | 50 |
current study | 50 |
bladder neck | 50 |
chest radiograph | 50 |
term outcomes | 50 |
often used | 50 |
body temperature | 50 |
outcome measure | 50 |
central venous | 50 |
will provide | 50 |
superior mesenteric | 50 |
study population | 50 |
healthy subjects | 50 |
postoperative pain | 50 |
conversion rate | 50 |
diff erences | 50 |
will help | 50 |
exome sequencing | 50 |
white blood | 50 |
clinically relevant | 50 |
genetic testing | 50 |
sentinel node | 50 |
echo sequence | 49 |
patients referred | 49 |
plasma cells | 49 |
absorbed dose | 49 |
days post | 49 |
years ago | 49 |
also performed | 49 |
neuro icu | 49 |
will present | 49 |
two independent | 49 |
clinical management | 49 |
clinically significant | 49 |
palliative care | 49 |
animal model | 49 |
doppler us | 49 |
chest radiography | 49 |
fi stula | 49 |
anatomical structures | 49 |
may improve | 49 |
low risk | 49 |
underwent mri | 48 |
extremely rare | 48 |
injured patients | 48 |
outcome scale | 48 |
medical image | 48 |
hematopoietic stem | 48 |
significantly decreased | 48 |
fast spin | 48 |
general surgery | 48 |
independent predictors | 48 |
patients included | 48 |
obese patients | 48 |
clinical setting | 48 |
mri may | 48 |
within months | 48 |
muscle weakness | 48 |
care units | 48 |
breast lesions | 48 |
eff ect | 48 |
paediatric patients | 48 |
connective tissue | 48 |
kidney disease | 48 |
well known | 48 |
peripheral nervous | 48 |
significant decrease | 48 |
clinical history | 48 |
peripheral nerves | 48 |
three cases | 48 |
vascular anomalies | 48 |
good correlation | 48 |
surgical management | 48 |
effective treatment | 47 |
transit time | 47 |
clinical manifestations | 47 |
temperature management | 47 |
mri examination | 47 |
mean duration | 47 |
childhood cancer | 47 |
tumour size | 47 |
back pain | 47 |
sciatic nerve | 47 |
developmental delay | 47 |
raw data | 47 |
neurological outcome | 47 |
gestational age | 47 |
icu los | 47 |
lung diseases | 47 |
future studies | 47 |
adipose tissue | 47 |
mri examinations | 47 |
low grade | 47 |
invasive approach | 47 |
axonal neuropathy | 47 |
imaging method | 47 |
intravenous injection | 47 |
growth factor | 46 |
type ii | 46 |
guided biopsy | 46 |
brachial plexus | 46 |
male patients | 46 |
significant changes | 46 |
mm collimation | 46 |
urinary incontinence | 46 |
pediatric radiologists | 46 |
first days | 46 |
patients suffering | 46 |
demyelinating polyneuropathy | 46 |
surg endosc | 46 |
cancer screening | 46 |
london uk | 46 |
interventional procedures | 46 |
male patient | 46 |
radiology department | 46 |
past medical | 46 |
imaging data | 46 |
clinical follow | 46 |
mri imaging | 46 |
scan time | 46 |
may present | 46 |
patient demographics | 46 |
first time | 46 |
fl uid | 46 |
first case | 46 |
mean value | 46 |
quality assurance | 46 |
recurrent disease | 46 |
female patient | 46 |
increasingly used | 46 |
diagnostic quality | 46 |
cerebral vasospasm | 46 |
one patients | 46 |
lower extremities | 46 |
positive results | 46 |
hiatal hernia | 45 |
vessel wall | 45 |
conservative treatment | 45 |
term outcome | 45 |
also found | 45 |
th ese | 45 |
anastomotic leak | 45 |
fi eld | 45 |
differentiated thyroid | 45 |
mr examinations | 45 |
ultrasound examination | 45 |
human body | 45 |
older age | 45 |
reference standard | 45 |
monoclonal antibody | 45 |
blood transfusion | 45 |
human brain | 45 |
tooth disease | 45 |
data analysis | 45 |
animal models | 45 |
renal arteries | 45 |
survival rates | 45 |
signal intensities | 45 |
renal disease | 45 |
diff erent | 45 |
core biopsy | 45 |
new york | 45 |
tr te | 45 |
early stages | 45 |
conventional imaging | 44 |
descriptive statistics | 44 |
cell proliferation | 44 |
data collection | 44 |
ct studies | 44 |
bone scan | 44 |
breast imaging | 44 |
fractional anisotropy | 44 |
neurological complications | 44 |
mesenteric artery | 44 |
trauma center | 44 |
gleason score | 44 |
motor neuron | 44 |
drug administration | 44 |
image analysis | 44 |
signifi cance | 44 |
mr examination | 44 |
normal controls | 44 |
limited data | 44 |
mm sec | 44 |
hospital admission | 44 |
marrow edema | 44 |
irb approval | 44 |
planar imaging | 44 |
bolus injection | 44 |
cell count | 44 |
cell death | 44 |
functional connectivity | 44 |
ionising radiation | 44 |
acute respiratory | 44 |
perfusion defects | 44 |
patient characteristics | 44 |
intensity projection | 44 |
significant association | 44 |
erectile dysfunction | 44 |
significant change | 44 |
brain tumours | 44 |
autoimmune diseases | 44 |
flip angle | 43 |
conduction block | 43 |
nerve injury | 43 |
stent placement | 43 |
brain lesions | 43 |
schwann cell | 43 |
plain radiography | 43 |
hip joint | 43 |
good results | 43 |
retrospectively analyzed | 43 |
pulmonary hypertension | 43 |
old boy | 43 |
maximum intensity | 43 |
contrast administration | 43 |
acute onset | 43 |
arrest patients | 43 |
liver function | 43 |
wall motion | 43 |
resonance spectroscopy | 43 |
liver parenchyma | 43 |
elevated icp | 43 |
mg ml | 43 |
emergency room | 43 |
roc curve | 43 |
vertebral artery | 43 |
disease duration | 43 |
images obtained | 43 |
within one | 43 |
low signal | 43 |
inguinal hernia | 43 |
lumbar puncture | 43 |
well established | 43 |
key role | 42 |
analysis using | 42 |
general population | 42 |
continuous eeg | 42 |
exact test | 42 |
motor neuropathy | 42 |
child abuse | 42 |
blood fl | 42 |
colorectal surgery | 42 |
blood pool | 42 |
randomized controlled | 42 |
left lateral | 42 |
parallel imaging | 42 |
complication rates | 42 |
scan showed | 42 |
phase encoding | 42 |
may represent | 42 |
blood supply | 42 |
cmt patients | 42 |
mr image | 42 |
liver resection | 42 |
fluorescence imaging | 42 |
hepatic artery | 42 |
imaging study | 42 |
prognostic value | 42 |
diabetic patients | 42 |
partial volume | 42 |
subdural hemorrhage | 42 |
met inclusion | 42 |
interstitial lung | 42 |
new technique | 42 |
studies showed | 42 |
prone position | 42 |
abdominal aorta | 42 |
lecture will | 42 |
technical success | 41 |
significantly correlated | 41 |
imaging appearances | 41 |
val met | 41 |
brain edema | 41 |
pulmonary arteries | 41 |
preliminary data | 41 |
spine mri | 41 |
care patients | 41 |
perfusion parameters | 41 |
identify patients | 41 |
renal transplantation | 41 |
mean operative | 41 |
gated spect | 41 |
radiological features | 41 |
frequently used | 41 |
operating characteristic | 41 |
axillary lymph | 41 |
plain films | 41 |
patients will | 41 |
autosomal dominant | 41 |
pregnant women | 41 |
medical management | 41 |
left ventricle | 41 |
underwent surgery | 41 |
ground glass | 41 |
icu stay | 41 |
conventional mri | 41 |
exhibit will | 41 |
doppler ultrasound | 41 |
better understand | 41 |
clinical significance | 41 |
using mri | 41 |
multidisciplinary team | 41 |
node biopsy | 40 |
square test | 40 |
spontaneous ich | 40 |
secondary outcomes | 40 |
blood samples | 40 |
partial response | 40 |
complications occurred | 40 |
past years | 40 |
pet scan | 40 |
mean difference | 40 |
brain barrier | 40 |
lesions may | 40 |
image processing | 40 |
resonance angiography | 40 |
mean values | 40 |
normal anatomy | 40 |
mr sequences | 40 |
ml sec | 40 |
type diabetes | 40 |
needle aspiration | 40 |
small number | 40 |
trend towards | 40 |
mild cognitive | 40 |
inferior vena | 40 |
months follow | 40 |
clinical studies | 40 |
serum creatinine | 40 |
nerve sheath | 40 |
wide variety | 40 |
function tests | 40 |
perfusion spect | 40 |
pediatric patient | 40 |
tumor volume | 40 |
prospective observational | 40 |
complete response | 40 |
filtered back | 40 |
imaging protocol | 39 |
ventricular drain | 39 |
clinical case | 39 |
studies suggest | 39 |
needle biopsy | 39 |
vast majority | 39 |
complete resolution | 39 |
motion artifacts | 39 |
aneurysmal sah | 39 |
reconstructed using | 39 |
cell lung | 39 |
fluid collections | 39 |
study suggests | 39 |
uptake value | 39 |
fat suppression | 39 |
squamous cell | 39 |
back projection | 39 |
pathologic correlation | 39 |
one third | 39 |
pancreatic duct | 39 |
brain ct | 39 |
autosomal recessive | 39 |
social media | 39 |
resolution ct | 39 |
will focus | 39 |
prospectively enrolled | 39 |
serum glucose | 39 |
images using | 39 |
operative complications | 39 |
acute chest | 39 |
vertebral body | 39 |
radiographic findings | 39 |
inflammatory diseases | 39 |
bowel disease | 39 |
less common | 39 |
patients compared | 38 |
matched controls | 38 |
kg body | 38 |
hodgkin lymphoma | 38 |
young patients | 38 |
day mortality | 38 |
brain spect | 38 |
amino acid | 38 |
comparative study | 38 |
congenital anomalies | 38 |
athens gr | 38 |
metabolic syndrome | 38 |
locally advanced | 38 |
survival rate | 38 |
postoperative course | 38 |
urinary bladder | 38 |
solid tumors | 38 |
arterial spin | 38 |
twenty patients | 38 |
remains unclear | 38 |
every hours | 38 |
patients reported | 38 |
imaging may | 38 |
specifi city | 38 |
often associated | 38 |
chain reaction | 38 |
ct fi | 38 |
many cases | 38 |
perfusion pressure | 38 |
control groups | 38 |
significantly greater | 38 |
average time | 38 |
histologically proven | 38 |
disease course | 38 |
performed within | 38 |
image contrast | 38 |
tumor cells | 38 |
power doppler | 38 |
thoracic aorta | 38 |
ct scanners | 38 |
perfusion ct | 38 |
several studies | 38 |
abdominal ultrasound | 38 |
retrospectively evaluated | 38 |
patients using | 38 |
ml kg | 38 |
intracranial aneurysms | 38 |
without contrast | 38 |
regression models | 38 |
progressive disease | 38 |
grade iii | 38 |
patients met | 38 |
ct image | 38 |
common complication | 38 |
mg day | 38 |
study shows | 38 |
peripheral neuropathies | 38 |
fi nding | 38 |
polymerase chain | 38 |
avascular necrosis | 37 |
laboratory data | 37 |
rating scale | 37 |
node metastases | 37 |
patient safety | 37 |
high incidence | 37 |
new approach | 37 |
inflammatory bowel | 37 |
small intestine | 37 |
infl ammation | 37 |
evoked potentials | 37 |
interobserver agreement | 37 |
cardiac cycle | 37 |
initial presentation | 37 |
every months | 37 |
multivariable logistic | 37 |
life threatening | 37 |
large vessel | 37 |
supportive care | 37 |
demographic data | 37 |
first year | 37 |
symptomatic patients | 37 |
cross sectional | 37 |
mouse model | 37 |
blood cells | 37 |
operative day | 37 |
cerebrovascular disease | 37 |
phase i | 37 |
time point | 37 |
including patients | 37 |
enhanced ultrasound | 37 |
oral contrast | 37 |
major complications | 37 |
perfusion scintigraphy | 37 |
cord injury | 37 |
patients enrolled | 37 |
study using | 37 |
mri features | 37 |
may benefit | 37 |
repetition time | 37 |
pet images | 37 |
breast mri | 37 |
intravenous contrast | 37 |
may play | 37 |
sensory loss | 37 |
cranial nerves | 37 |
thyroid gland | 37 |
operating time | 37 |
two experienced | 37 |
radiologic findings | 37 |
radiological findings | 36 |
larmor frequency | 36 |
teaching points | 36 |
incisional hernia | 36 |
active disease | 36 |
foreign bodies | 36 |
radical cystectomy | 36 |
three years | 36 |
patients experienced | 36 |
cancer surgery | 36 |
mri scan | 36 |
portal hypertension | 36 |
icu patients | 36 |
medical device | 36 |
five years | 36 |
may contribute | 36 |
enhanced mra | 36 |
various imaging | 36 |
reconstruction algorithm | 36 |
gr purpose | 36 |
investigate whether | 36 |
combination therapy | 36 |
diffusion imaging | 36 |
percutaneous drainage | 36 |
may reduce | 36 |
may reflect | 36 |
subjective image | 36 |
upper extremity | 36 |
patient showed | 36 |
examination showed | 36 |
turbo spin | 36 |
early onset | 36 |
imaging protocols | 36 |
radiation doses | 36 |
axial images | 36 |
imaging procedures | 36 |
phase contrast | 36 |
positive patients | 36 |
without evidence | 36 |
significantly improved | 36 |
spect images | 36 |
data collected | 36 |
spinal injury | 36 |
stable disease | 35 |
small fiber | 35 |
vascular lesions | 35 |
hospital length | 35 |
two months | 35 |
nerve palsy | 35 |
clinical audit | 35 |
tract infections | 35 |
functional recovery | 35 |
pathological changes | 35 |
high mortality | 35 |
focal lesions | 35 |
progressive ms | 35 |
icg fluorescence | 35 |
successfully treated | 35 |
spine injury | 35 |
showed increased | 35 |
correlation coefficients | 35 |
brain atrophy | 35 |
using different | 35 |
poorly understood | 35 |
clinical deterioration | 35 |
diffusion restriction | 35 |
invasive method | 35 |
multivariate logistic | 35 |
chronic progressive | 35 |
independent risk | 35 |
will allow | 35 |
whole brain | 35 |
lung parenchyma | 35 |
lower urinary | 35 |
small cell | 35 |
pulse sequence | 35 |
anastomotic leakage | 35 |
clinical relevance | 35 |
foreign body | 35 |
phase ii | 35 |
us purpose | 35 |
performed without | 35 |
using standard | 35 |
significantly better | 35 |
general hospital | 35 |
rare case | 35 |
ct scanning | 35 |
pediatric hematology | 35 |
true positive | 35 |
dorsal root | 35 |
three days | 35 |
studied patients | 35 |
patient data | 35 |
pediatric cancer | 34 |
magnetization components | 34 |
mg i | 34 |
left sided | 34 |
residual disease | 34 |
two readers | 34 |
photon emission | 34 |
within weeks | 34 |
hospital day | 34 |
abdominal trauma | 34 |
review board | 34 |
clinical assessment | 34 |
malignant tumors | 34 |
ovarian cancer | 34 |
iv contrast | 34 |
technical aspects | 34 |
functional information | 34 |
flow velocity | 34 |
mean hospital | 34 |
whole exome | 34 |
frontal lobe | 34 |
routinely used | 34 |
high quality | 34 |
posterior reversible | 34 |
two days | 34 |
prospective cohort | 34 |
erectile function | 34 |
experienced radiologists | 34 |
steroid therapy | 34 |
kidney injury | 34 |
myocardial ischemia | 34 |
autoimmune disease | 34 |
patient dose | 34 |
clinically suspected | 34 |
joint space | 34 |
therapeutic approach | 34 |
determined using | 34 |
urothelial carcinoma | 34 |
time interval | 34 |
carotid arteries | 34 |
fl exible | 34 |
also known | 34 |
also observed | 34 |
side effect | 34 |
side eff | 34 |
time consuming | 34 |
mean arterial | 34 |
data regarding | 34 |
replacement therapy | 34 |
major cause | 34 |
surgical techniques | 34 |
medical systems | 34 |
nerve biopsy | 34 |
serum levels | 34 |
proton density | 34 |
brain regions | 34 |
intravenous administration | 34 |
rank test | 34 |
grade gliomas | 34 |
transverse colon | 34 |
using two | 34 |
tof mra | 34 |
monte carlo | 33 |
session will | 33 |
cardiovascular disease | 33 |
enhancing lesions | 33 |
grey matter | 33 |
vascular disease | 33 |
cell transplant | 33 |
using high | 33 |
plain film | 33 |
laboratory findings | 33 |
echo planar | 33 |
aortic dissection | 33 |
study demonstrates | 33 |
cardiac mri | 33 |
correlated well | 33 |
transplant recipients | 33 |
perfusion studies | 33 |
academic medical | 33 |
conventional angiography | 33 |
first group | 33 |
commonly seen | 33 |
conduction velocities | 33 |
estimated blood | 33 |
wilms tumor | 33 |
cystic lesion | 33 |
coronavirus disease | 33 |
comatose patients | 33 |
mr findings | 33 |
encephalopathy syndrome | 33 |
one hour | 33 |
abusive head | 33 |
examinations performed | 33 |
current modulation | 33 |
patients affected | 33 |
cancer detection | 33 |
vertebral bodies | 33 |
detector row | 33 |
pain score | 33 |
neural networks | 33 |
asymptomatic patients | 33 |
motor function | 33 |
patients requiring | 33 |
normal values | 33 |
renal transplant | 33 |
one ferret | 33 |
spinal sdh | 33 |
ulcerative colitis | 33 |
invasive technique | 33 |
admission gcs | 33 |
many years | 33 |
aged years | 33 |
thyroid nodules | 33 |
normal saline | 33 |
skin biopsy | 33 |
brain stem | 33 |
appropriate treatment | 33 |
mitral valve | 33 |
mechanical thrombectomy | 33 |
regional cerebral | 33 |
focal liver | 33 |
hess grade | 33 |
doppler sonography | 33 |
tumor necrosis | 33 |
bile ducts | 33 |
bone lesions | 33 |
groups according | 33 |
common bile | 32 |
initial experience | 32 |
mcg ml | 32 |
ad patients | 32 |
severe acute | 32 |
will include | 32 |
acute neurological | 32 |
patients whose | 32 |
high levels | 32 |
mr scanner | 32 |
intestinal obstruction | 32 |
diagnostic work | 32 |
response rate | 32 |
ex vivo | 32 |
different levels | 32 |
mri data | 32 |
autoimmune hypophysitis | 32 |
various types | 32 |
considered significant | 32 |
relatively low | 32 |
may increase | 32 |
routine clinical | 32 |
amino acids | 32 |
biliary tract | 32 |
chronic pancreatitis | 32 |
without complications | 32 |
patient group | 32 |
widely accepted | 32 |
oncological outcomes | 32 |
right hemicolectomy | 32 |
plain radiographs | 32 |
lung function | 32 |
mri revealed | 32 |
adrenal gland | 32 |
risk stratification | 32 |
laboratory tests | 32 |
acute abdomen | 32 |
ultrasound guidance | 32 |
protocol included | 32 |
higher rates | 32 |
cancer diagnosis | 32 |
diffusion gradients | 32 |
conduction velocity | 32 |
symptom score | 32 |
encoding gradient | 32 |
per day | 32 |
reversible encephalopathy | 32 |
ct may | 32 |
also evaluated | 32 |
us findings | 32 |
cardiac surgery | 32 |
evaluate whether | 32 |
pet studies | 32 |
daily living | 32 |
nk cells | 32 |
slowly progressive | 32 |
may serve | 32 |
well described | 32 |
patients also | 32 |
endothelial cells | 32 |
cantly higher | 32 |
conventional radiography | 32 |
total gastrectomy | 32 |
cystic duct | 32 |
last decade | 32 |
similar results | 32 |
patient selection | 32 |
primary endpoint | 32 |
carpal tunnel | 32 |
te ms | 32 |
body ct | 32 |
myeloid leukemia | 32 |
field strengths | 32 |
lesion size | 32 |
clinical application | 32 |
surgical planning | 32 |
multidisciplinary approach | 31 |
high diagnostic | 31 |
arterial pressure | 31 |
primary tumor | 31 |
cases showed | 31 |
posterior circulation | 31 |
higher rate | 31 |
complete remission | 31 |
clinical presentations | 31 |
well defined | 31 |
hematoma volume | 31 |
portal venous | 31 |
reactive protein | 31 |
blood count | 31 |
years later | 31 |
ct mri | 31 |
pulmonary edema | 31 |
brain showed | 31 |
phase iii | 31 |
mri study | 31 |
tracer uptake | 31 |
institutional review | 31 |
controlled trials | 31 |
central line | 31 |
within minutes | 31 |
sural nerve | 31 |
cognitive function | 31 |
imaging evaluation | 31 |
distant metastasis | 31 |
interquartile range | 31 |
may require | 31 |
major bleeding | 31 |
multiple myeloma | 31 |
high morbidity | 31 |
discharge disposition | 31 |
classified according | 31 |
altered mental | 31 |
clinical phenotype | 31 |
iron oxide | 31 |
hospital medical | 31 |
lupus erythematosus | 31 |
serum sodium | 31 |
neural network | 31 |
neurocritically ill | 31 |
year survival | 31 |
rotation time | 31 |
apnea testing | 31 |
renal mass | 31 |
without significant | 31 |
identifi cation | 31 |
contrast resolution | 31 |
negative results | 31 |
also used | 31 |
improve patient | 31 |
showed high | 31 |
low levels | 31 |
ct guided | 31 |
marrow transplantation | 31 |
image gently | 31 |
chronic pain | 31 |
assess whether | 31 |
quantitative evaluation | 31 |
tumor growth | 31 |
second group | 31 |
one child | 31 |
based approach | 31 |
guided percutaneous | 31 |
statistical difference | 31 |
images showed | 31 |
flux density | 31 |
neurologic outcome | 31 |
target temperature | 31 |
immune system | 31 |
progressive multiple | 30 |
clinical routine | 30 |
neurointensive care | 30 |
surgical repair | 30 |
small sample | 30 |
malignant melanoma | 30 |
renal dysfunction | 30 |
chemical shift | 30 |
infl uence | 30 |
ischemic injury | 30 |
laparoscopic repair | 30 |
oligoclonal bands | 30 |
severe brain | 30 |
calcium score | 30 |
adverse reactions | 30 |
femoral neck | 30 |
repeat imaging | 30 |
seoul kr | 30 |
previously healthy | 30 |
significant impact | 30 |
expression levels | 30 |
arterial blood | 30 |
neurological outcomes | 30 |
johns hopkins | 30 |
group consisted | 30 |
cerebral venous | 30 |
provide additional | 30 |
inflammatory disease | 30 |
intended use | 30 |
within normal | 30 |
screening tool | 30 |
anterior wall | 30 |
significantly less | 30 |
cervical spinal | 30 |
decision support | 30 |
single slice | 30 |
best practice | 30 |
may allow | 30 |
study demonstrated | 30 |
clinical response | 30 |
cardiovascular risk | 30 |
targeted therapies | 30 |
fat saturation | 30 |
contrast injection | 30 |
inflammatory response | 30 |
pet mri | 30 |
retrospective case | 30 |
biliary tree | 30 |
mean transit | 30 |
important information | 30 |
worse outcomes | 30 |
general electric | 30 |
coil embolization | 30 |
two observers | 30 |
dual energy | 30 |
first report | 30 |
study design | 30 |
mean number | 30 |
gastroesophageal reflux | 30 |
cancer survivors | 30 |
near future | 30 |
drain placement | 30 |
systemic lupus | 30 |
less invasive | 30 |
pulmonary venous | 30 |
term results | 30 |
deep venous | 30 |
respiratory tract | 30 |
underwent surgical | 30 |
criteria included | 30 |
vascular access | 30 |
remaining cases | 30 |
observational cohort | 30 |
imaging showed | 30 |
body mri | 30 |
acquisition parameters | 30 |
group showed | 30 |
positive rate | 30 |
highly sensitive | 30 |
hours prior | 29 |
patient died | 29 |
tissue oxygen | 29 |
daily practice | 29 |
less frequently | 29 |
hepatic vein | 29 |
primary diagnosis | 29 |
total thyroidectomy | 29 |
clinical value | 29 |
renal tumors | 29 |
unique teaching | 29 |
viral infection | 29 |
overall image | 29 |
marrow oedema | 29 |
right ventricular | 29 |
grade ii | 29 |
sensory neuropathy | 29 |
results demonstrate | 29 |
significant morbidity | 29 |
published data | 29 |
examined using | 29 |
scatter correction | 29 |
results obtained | 29 |
node metastasis | 29 |
acute kidney | 29 |
mri demonstrated | 29 |
showed diffuse | 29 |
distant metastases | 29 |
pulmonary angiography | 29 |
head gamma | 29 |
catheter angiography | 29 |
decompressive hemicraniectomy | 29 |
pain scores | 29 |
educational content | 29 |
significant risk | 29 |
glucose metabolism | 29 |
hemolytic anemia | 29 |
testicular torsion | 29 |
volume zoom | 29 |
lesion detection | 29 |
resting state | 29 |
pulmonary arterial | 29 |
retrospective observational | 29 |
four groups | 29 |
cell line | 29 |
dynamic mri | 29 |
peripheral arterial | 29 |
pediatric radiologist | 29 |
may mimic | 29 |
demyelinating neuropathy | 29 |
collecting system | 29 |
botulinum toxin | 29 |
body scan | 29 |
tr ms | 29 |
normal variants | 29 |
solid organ | 29 |
uk learning | 29 |
improve outcomes | 29 |
done using | 29 |
upper gastrointestinal | 29 |
twelve patients | 29 |
lateral sclerosis | 29 |
risk group | 29 |
using ct | 29 |
total mesorectal | 29 |
based contrast | 29 |
liver transplantation | 29 |
rotator cuff | 29 |
fine needle | 29 |
current literature | 29 |
ewing sarcoma | 29 |
time period | 29 |
amyotrophic lateral | 29 |
care society | 29 |
findings included | 29 |
months aft | 29 |
initial ct | 29 |
findings may | 29 |
may show | 29 |
relapse rate | 29 |
multimodal imaging | 29 |
gi tract | 29 |
multivariable analysis | 29 |
saline solution | 29 |
hospital course | 29 |
tyrosine kinase | 29 |
flow rate | 29 |
acquired using | 29 |
immunocompromised patients | 29 |
group compared | 29 |
standard treatment | 29 |
blue dye | 29 |
acute pancreatitis | 29 |
elevated intracranial | 29 |
acute myeloid | 29 |
axonal degeneration | 29 |
also showed | 29 |
placebo group | 28 |
data will | 28 |
pet scans | 28 |
clinical research | 28 |
stroke center | 28 |
relatively high | 28 |
host disease | 28 |
demyelinating polyradiculoneuropathy | 28 |
cell histiocytosis | 28 |
cc parcellation | 28 |
three times | 28 |
neurological disorders | 28 |
rare complication | 28 |
prostate volume | 28 |
patient outcome | 28 |
neurological exam | 28 |
sectional area | 28 |
image interpretation | 28 |
gastrointestinal bleeding | 28 |
tube placement | 28 |
aortic aneurysm | 28 |
potential complications | 28 |
western blot | 28 |
gcs score | 28 |
least two | 28 |
birth weight | 28 |
slice width | 28 |
percutaneous nephrolithotomy | 28 |
crucial role | 28 |
skin biopsies | 28 |
clinical picture | 28 |
medical students | 28 |
apnea test | 28 |
roc analysis | 28 |
least months | 28 |
public health | 28 |
initial diagnosis | 28 |
pathological conditions | 28 |
sh tc | 28 |
educational exhibit | 28 |
ray imaging | 28 |
trauma patients | 28 |
emission computed | 28 |
upper limbs | 28 |
segment model | 28 |
will describe | 28 |
old patient | 28 |
temporal bone | 28 |
nerve fiber | 28 |
glomerular filtration | 28 |
healthy donors | 28 |
younger patients | 28 |
early postoperative | 28 |
esophageal cancer | 28 |
upper urinary | 28 |
information regarding | 28 |
magnetization transfer | 28 |
muscle biopsy | 28 |
pain control | 28 |
enhancement pattern | 28 |
neuromyelitis optica | 28 |
eleven patients | 28 |
ct protocols | 28 |
patienten mit | 28 |
hyperintense lesions | 28 |
colour doppler | 28 |
mcg kg | 28 |
post operative | 28 |
mesorectal excision | 28 |
previously published | 28 |
imaging system | 28 |
us examination | 28 |
da vinci | 28 |
normal tissue | 28 |
patients demonstrated | 28 |
contrast images | 28 |
stone size | 28 |
preliminary study | 28 |
following parameters | 28 |
basic protein | 28 |
overall sensitivity | 28 |
rare disease | 28 |
transfer learning | 28 |
myelin basic | 28 |
icp monitoring | 28 |
clinical cases | 28 |
data points | 28 |
lymphocytic hypophysitis | 28 |
hemorrhagic stroke | 28 |
magnetic flux | 28 |
fold increase | 28 |
radioiodine therapy | 28 |
functional status | 28 |
bone mineral | 28 |
icu length | 28 |
pelvic pain | 28 |
underwent ct | 28 |
negative correlation | 27 |
studies performed | 27 |
weighted spin | 27 |
thyroid tissue | 27 |
cell carcinomas | 27 |
recent advances | 27 |
mediastinal lymph | 27 |
sonographic findings | 27 |
grade i | 27 |
type iii | 27 |
clinical experience | 27 |
characteristic imaging | 27 |
day post | 27 |
major role | 27 |
ultrasound contrast | 27 |
virtual endoscopy | 27 |
commonly encountered | 27 |
may include | 27 |
hospitalized patients | 27 |
higher sensitivity | 27 |
septic shock | 27 |
factor viii | 27 |
qualitative analysis | 27 |
signal changes | 27 |
air trapping | 27 |
hepatic lesions | 27 |
five cases | 27 |
good clinical | 27 |
potential therapeutic | 27 |
cox regression | 27 |
facial nerve | 27 |
rare entity | 27 |
chest syndrome | 27 |
patients submitted | 27 |
will show | 27 |
time window | 27 |
elevated serum | 27 |
without clinical | 27 |
children aged | 27 |
anterior resection | 27 |
fi brosis | 27 |
spot sign | 27 |
per week | 27 |
high rate | 27 |
left kidney | 27 |
urinary retention | 27 |
identified using | 27 |
primary tumour | 27 |
neoadjuvant chemotherapy | 27 |
two main | 27 |
magnetic moment | 27 |
widely available | 27 |
university medical | 27 |
invasive procedures | 27 |
viral infections | 27 |
new lesions | 27 |
tract symptoms | 27 |
clinical utility | 27 |
systolic blood | 27 |
panel detector | 27 |
next generation | 27 |
evd placement | 27 |
ct study | 27 |
articular cartilage | 27 |
thermal ablation | 27 |
high accuracy | 27 |
mri scanner | 27 |
may affect | 27 |
gradient field | 27 |
retrospectively collected | 27 |
operating room | 27 |
adc maps | 27 |
staging system | 27 |
radiological appearances | 27 |
mr contrast | 27 |
healthy control | 27 |
joint collapse | 27 |
interobserver variability | 27 |
trabecular bone | 27 |
hunt hess | 27 |
four cases | 27 |
organ donation | 27 |
phase images | 27 |
outcomes included | 27 |
first study | 27 |
contrast ct | 27 |
diabetes insipidus | 27 |
pulmonary function | 27 |
grade iv | 27 |
small renal | 27 |
standard protocol | 27 |
short axis | 27 |
sagittal plane | 27 |
ascending aorta | 27 |
provide information | 27 |
classification accuracy | 27 |
measurement time | 27 |
ow rate | 27 |
axonal injury | 27 |
physical activity | 27 |
favorable outcome | 27 |
cardiac function | 27 |
surgical excision | 27 |
stage i | 27 |
sensory symptoms | 27 |
surgical decompression | 27 |
gradient fields | 27 |
stroke scale | 26 |
group included | 26 |
materials methods | 26 |
post injection | 26 |
fifteen patients | 26 |
mm trocar | 26 |
treatment group | 26 |
gre sequences | 26 |
early treatment | 26 |
national institute | 26 |
high correlation | 26 |
also significantly | 26 |
procedures performed | 26 |
surgical complications | 26 |
high degree | 26 |
sensory nerve | 26 |
th ree | 26 |
results will | 26 |
male presented | 26 |
stage renal | 26 |
peptic ulcer | 26 |
frequently observed | 26 |
robotic system | 26 |
added value | 26 |
gbs disability | 26 |
year os | 26 |
analysed using | 26 |
common causes | 26 |
highly variable | 26 |
showed improvement | 26 |
many different | 26 |
somatostatin receptor | 26 |
currently available | 26 |
epileptiform discharges | 26 |
hematology oncology | 26 |
time course | 26 |
endoscopic surgery | 26 |
occlusive disease | 26 |
initial imaging | 26 |
peritoneal cavity | 26 |
benign prostatic | 26 |
myelin protein | 26 |
first reported | 26 |
generation sequencing | 26 |
right upper | 26 |
residual urine | 26 |
eeg monitoring | 26 |
emergency surgery | 26 |
images acquired | 26 |
rib fractures | 26 |
preoperative diagnosis | 26 |
i ml | 26 |
neurology residents | 26 |
osteoid osteoma | 26 |
wound infection | 26 |
conventional mr | 26 |
outcome data | 26 |
bone scans | 26 |
presenting symptoms | 26 |
drg neurons | 26 |
valuable tool | 26 |
showed significantly | 26 |
american college | 26 |
venous system | 26 |
ge healthcare | 26 |
primary objective | 26 |
diaphragmatic hernia | 26 |
diagnostic information | 26 |
liver cirrhosis | 26 |
tse sequence | 26 |
flow measurements | 26 |
bone tumours | 26 |
cell lymphoma | 26 |
unknown origin | 26 |
nissen fundoplication | 26 |
source ct | 26 |
clinical evidence | 26 |
disease processes | 26 |
system using | 26 |
clinical indications | 26 |
renal pelvis | 26 |
digital radiography | 26 |
mm thick | 26 |
platelet counts | 26 |
clinical care | 26 |
inferior mesenteric | 26 |
differ significantly | 26 |
potential pitfalls | 26 |
water molecules | 26 |
response assessment | 26 |
female pelvis | 26 |
brain parenchyma | 26 |
post mortem | 26 |
mog antibodies | 26 |
abnormal findings | 26 |
voxel size | 26 |
routine use | 26 |
mgi ml | 26 |
negative patients | 26 |
artery occlusion | 26 |
continuous infusion | 26 |
general anaesthesia | 26 |
may become | 26 |
first months | 26 |
vital signs | 26 |
disease process | 26 |
laparoscopic gastrectomy | 26 |
new method | 26 |
regression analyses | 26 |
external magnetic | 26 |
four hours | 26 |
two methods | 26 |
spine injuries | 26 |
postoperative morbidity | 26 |
sensory neurons | 26 |
line treatment | 26 |
fatty acids | 26 |
proposed method | 26 |
thrombolytic therapy | 26 |
multidetector row | 26 |
imaging sequences | 26 |
liver biopsy | 26 |
modifi ed | 26 |
neurological deterioration | 26 |
lesions showed | 26 |
mri using | 26 |
relatively common | 26 |
recent study | 26 |
incidental findings | 26 |
median duration | 26 |
adc value | 26 |
neurological status | 25 |
glass opacity | 25 |
laparoscopic partial | 25 |
imaging parameters | 25 |
apache ii | 25 |
individual patients | 25 |
vascular malformation | 25 |
pivotal role | 25 |
cd cd | 25 |
medical complications | 25 |
autonomic dysfunction | 25 |
hospital los | 25 |
medical therapy | 25 |
axonal loss | 25 |
evidence suggests | 25 |
body composition | 25 |
patient required | 25 |
organ failure | 25 |
amyloid angiopathy | 25 |
long time | 25 |
advanced imaging | 25 |
imaging will | 25 |
stage iii | 25 |
tunnel syndrome | 25 |
paediatric neurology | 25 |
splenic flexure | 25 |
patient satisfaction | 25 |
csf analysis | 25 |
larger number | 25 |
laparoscopic right | 25 |
robotic approach | 25 |
severe disability | 25 |
invasive surgical | 25 |
gadopentate dimeglumine | 25 |
convolutional neural | 25 |
clinical decision | 25 |
diabetic neuropathy | 25 |
chronic kidney | 25 |
ct brain | 25 |
post contrast | 25 |
arterial disease | 25 |
standard dose | 25 |
targeted temperature | 25 |
conduction study | 25 |
showed good | 25 |
long axis | 25 |
mineral density | 25 |
several days | 25 |
remitting multiple | 25 |
potential role | 25 |
subchondral bone | 25 |
diagnostic yield | 25 |
marrow failure | 25 |
multimodal neuroimaging | 25 |
definitive diagnosis | 25 |
intravascular contrast | 25 |
treatment may | 25 |
metastatic lesions | 25 |
upper limb | 25 |
matter tracts | 25 |
cervical lymph | 25 |
flat panel | 25 |
enhanced magnetic | 25 |
hemorrhagic transformation | 25 |
currently used | 25 |
readily available | 25 |
reconstructed images | 25 |
salivary glands | 25 |
fi stulas | 25 |
pulmonary vein | 25 |
right colectomy | 25 |
total body | 25 |
ct angiogram | 25 |
interim analysis | 25 |
laparoscopic colorectal | 25 |
normal limits | 25 |
whitney test | 25 |
hospital death | 25 |
bone pain | 25 |
cant correlation | 25 |
sigmoid colon | 25 |
safe procedure | 25 |
may indicate | 25 |
glass opacities | 25 |
surface area | 25 |
also present | 25 |
disability score | 25 |
clinical parameters | 25 |
heterogeneous group | 25 |
refl ux | 25 |
additional imaging | 25 |
glucose levels | 25 |
neurological emergencies | 25 |
broad spectrum | 25 |
performed laparoscopic | 25 |
seven days | 25 |
cns infections | 25 |
right lateral | 25 |
affected patients | 25 |
mdct angiography | 25 |
new imaging | 25 |
high prevalence | 25 |
patients within | 25 |
beam ct | 25 |
high field | 25 |
neurosurgical intervention | 25 |
local anesthesia | 25 |
radiological fi | 25 |
treated group | 25 |
may need | 24 |
strongly associated | 24 |
physical exam | 24 |
tumor recurrence | 24 |
storage phosphor | 24 |
image registration | 24 |
randomly assigned | 24 |
single port | 24 |
intraparenchymal hemorrhage | 24 |
previous study | 24 |
promising results | 24 |
mass lesions | 24 |
reference levels | 24 |
diagnostic confidence | 24 |
acute cholecystitis | 24 |
acquisition times | 24 |
right ventricle | 24 |
cerebral aneurysms | 24 |
colic artery | 24 |
multimodality imaging | 24 |
mean length | 24 |
energy ct | 24 |
seizure activity | 24 |
mri sequences | 24 |
one day | 24 |
cell viability | 24 |
small animals | 24 |
will illustrate | 24 |
normal control | 24 |
tumour recurrence | 24 |
urethral stricture | 24 |
ct revealed | 24 |
ct system | 24 |
techniques will | 24 |
many studies | 24 |
young people | 24 |
data indicate | 24 |
inversion pulse | 24 |
medical school | 24 |
computed tomographic | 24 |
preoperative assessment | 24 |
using ultrasound | 24 |
recently published | 24 |
metabolic acidosis | 24 |
musculoskeletal system | 24 |
pixel size | 24 |
tnm staging | 24 |
vasogenic edema | 24 |
rf field | 24 |
fi lms | 24 |
study provides | 24 |
non invasive | 24 |
four weeks | 24 |
may develop | 24 |
upper abdomen | 24 |
new onset | 24 |
term effects | 24 |
distal pancreatectomy | 24 |
increased mortality | 24 |
total patients | 24 |
subjects underwent | 24 |
weighted image | 24 |
acute renal | 24 |
inflammatory changes | 24 |
short term | 24 |
mri protocol | 24 |
another patient | 24 |
project description | 24 |
positively correlated | 24 |
several clinical | 24 |
irb approved | 24 |
physical therapy | 24 |
testing revealed | 24 |
increased signal | 24 |
video shows | 24 |
categorical variables | 24 |
medical images | 24 |
increased intracranial | 24 |
assisted surgery | 24 |
low cost | 24 |
comprehensive stroke | 24 |
different clinical | 24 |
infectious diseases | 24 |
axial plane | 24 |
remains controversial | 24 |
mechanically ventilated | 24 |
spinal canal | 24 |
histopathological examination | 24 |
demyelinating disease | 24 |
male gender | 24 |
right kidney | 24 |
relative risk | 24 |
false positives | 24 |
quantitative assessment | 24 |
cancer treatment | 24 |
case highlights | 24 |
mean score | 24 |
excluded patients | 24 |
will require | 24 |
abdominal surgery | 24 |
deep learning | 24 |
gadolinium enhancement | 24 |
late complications | 24 |
magnetization mxy | 24 |
jugular vein | 24 |
initial treatment | 24 |
histopathological findings | 24 |
much higher | 24 |
source images | 24 |
coronary ct | 24 |
pictorial essay | 24 |
surgical outcomes | 24 |
sinus thrombosis | 24 |
right posterior | 24 |
therapy may | 24 |
neurological signs | 24 |
imaging appearance | 24 |
accidental trauma | 24 |
cm sec | 24 |
analysis included | 24 |
splenic artery | 24 |
mr perfusion | 24 |
randomized trial | 24 |
focused ultrasound | 24 |
radiologic features | 24 |
disease onset | 24 |
excitation pulse | 24 |
wilcoxon signed | 24 |
paris fr | 24 |
fi nal | 24 |
assisted laparoscopic | 24 |
internal capsule | 24 |
rf ablation | 24 |
fr purpose | 24 |
right lower | 24 |
acquisition protocol | 24 |
group patients | 24 |
may suggest | 24 |
clinical status | 24 |
poor functional | 24 |
rare cause | 24 |
spin system | 23 |
intraoperative complications | 23 |
i will | 23 |
increased uptake | 23 |
controlled study | 23 |
prostatic hyperplasia | 23 |
brain injuries | 23 |
diagnostic workup | 23 |
standardized uptake | 23 |
effective method | 23 |
findings will | 23 |
standard deviations | 23 |
average number | 23 |
cant difference | 23 |
preoperative evaluation | 23 |
imaging sequence | 23 |
ultrasound guided | 23 |
good outcomes | 23 |
arteriovenous malformation | 23 |
mononuclear cells | 23 |
also associated | 23 |
perfusion mri | 23 |
root ganglia | 23 |
frequently associated | 23 |
muscle strength | 23 |
stage iv | 23 |
increased incidence | 23 |
uterine artery | 23 |
treatment strategies | 23 |
juvenile idiopathic | 23 |
comparative analysis | 23 |
vascular anatomy | 23 |
plasminogen activator | 23 |
sectional study | 23 |
using low | 23 |
grade sah | 23 |
mesenteric vein | 23 |
arterial hypertension | 23 |
modified fisher | 23 |
normal appearing | 23 |
anoxic brain | 23 |
eligible patients | 23 |
paediatric population | 23 |
imaging tool | 23 |
young adult | 23 |
anatomic structures | 23 |
computer tomography | 23 |
different modalities | 23 |
cerebral angiography | 23 |
mean adc | 23 |
middle colic | 23 |
kidney function | 23 |
mri will | 23 |
subcortical white | 23 |
single dose | 23 |
dedicated software | 23 |
fi lled | 23 |
brain mr | 23 |
initial gcs | 23 |
diagnostic procedures | 23 |
complications related | 23 |
last two | 23 |
optimal cut | 23 |
new therapeutic | 23 |
internal hernia | 23 |
temporal lobes | 23 |
first pass | 23 |
repetition times | 23 |
thoracic aortic | 23 |
malignant tumours | 23 |
large volume | 23 |
information provided | 23 |
neuroendocrine tumours | 23 |
abdominal aortic | 23 |
randomly selected | 23 |
commonly performed | 23 |
last year | 23 |
within years | 23 |
ventral hernia | 23 |
single institution | 23 |
ulnar nerve | 23 |
aortic valve | 23 |
cystic masses | 23 |
urine volume | 23 |
gradient coils | 23 |
ibd patients | 23 |
solid tumours | 23 |
nerve regeneration | 23 |
data suggests | 23 |
strong correlation | 23 |
bowel loops | 23 |
prognostic information | 23 |
brain tumour | 23 |